TLC to Present at 38th Annual JP Morgan Healthcare Conference
02 janv. 2020 04h00 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Jan. 02, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC Announces First Patient Enrollment in EXCELLENCE Trial Evaluating Single and Repeat Administrations of TLC599
27 nov. 2019 04h30 HE
|
TLC
Phase III clinical trial of TLC599 to recruit 500 patients with moderate to severe symptomatic knee osteoarthritis Patients can receive two injections of placebo or drugPatient enrollment expected to...
TLC Announces Completion of US$27 Million Financing
24 oct. 2019 05h00 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 24, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC Reports Third Quarter 2019 Financial Results and Provides Business Update
22 oct. 2019 06h09 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 22, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC Presents Clinical and Preclinical Data of TLC590 at ANESTHESIOLOGY® Annual Meeting and in International Journal of Nanomedicine
21 oct. 2019 05h24 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 21, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC Appoints Vincent Chang, PhD, as Vice President of Manufacturing Development
20 oct. 2019 04h10 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 20, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC to Present Potential Cartilage-Protecting Effects of TLC599 on the Knee at 2019 ACR Annual Meeting
07 oct. 2019 04h30 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 07, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC Announces Initiation of Phase III Pivotal Clinical Trial of TLC599 for the Treatment of Osteoarthritis Knee Pain
01 oct. 2019 04h30 HE
|
TLC
- Phase II results showed statistically significant pain relief through 24 weeks- Phase III to evaluate efficacy of single and repeated doses up to 52 weeks SOUTH SAN FRANCISCO, Calif. and TAIPEI,...
TLC to Present Preclinical Data on TLC178 at ESMO 2019
23 sept. 2019 05h00 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 23, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC to Present as Panelist among Key Opinion Leaders at the BTIG Pain Management Forum
03 sept. 2019 06h04 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 03, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152) announced today that the Company’s management team has been invited to participate in...